Table 3.
Summary of the included amyloid-PET studies included with LHR and GRADE analysis.
| Authors | Population | Method | Cohort investigated | Follow-up months | Sens. | Spec. | LHR+ | Increase in the LHR+ | Quality of evidence (GRADE) |
|---|---|---|---|---|---|---|---|---|---|
| Barthel et al., 2011 [96, 97] | 81 AD; 69 HC | ROI SUVR analysis | 81 | — | 0.85 | 0.91 | 9.44 | Moderate | M |
| Rabinovici et al., 2011 [34] | 62 AD; 45 FTD | ROI DVR analysis | 107 | 12 | 0.89 | 0.83 | 5.24 | Moderate | M |
| Rostomian et al., 2011 [58] | 42 AD; 31 FTD | ROI DVR analysis | 73 | 16 | 0.905 | 0.84 | 5.66 | Moderate | M |
| Rowe et al., 2008 [93] | 15 AD; 5 FTD; 15 HC | SUVR analysis | 20 | 12 | 1 | 0.9 | 10.00 | Moderate | L |
| Villemagne et al., 2011 [12] | 30 AD; 20 MCI; 32 HC; 11 FTD; 7 LBD; 5 PD; 4 VaD | SUVR analysis | 30 | — | 0.97 | 0.84 | 6.06 | Moderate | M |
| Clark et al., 2012 [102] | 5 MCI; 29 AD; 12 HC; 13 ODD | SUVR analysis | 47 | 24 | 0.97 | 0.99 | 97.00 | Large | M |
| Camus et al., 2012 [29] | 13 AD; 12 MCI; 21 HC | SUVR + Visual | 13 | — | 0.923 | 0.905 | 9.72 | Moderate | VL |
| Koivunen et al., 2011 [62] | 29 MCI; 13 HC | PiB retention analysis | 29 | 24 | 0.94 | 0.42 | 1.62 | Minimal | VL |
| Mosconi et al., 2009 [19] | 31 MCI | ROI ratio SPM | 31 | 32.16 | 0.93 | 0.76 | 3.88 | Small | L |
| Forsberg et al., 2010 [100] | 37 mild AD; 21 MCI | ROI ratio SPM | 58 | 33 | 1 | 0.71 | 3.45 | Small | L |
| Jack et al., 2010 [46] | 53 MCI | DVR | 53 | 20.4 | 0.83 | 0.46 | 1.54 | Minimal | VL |
| Wolk et al., 2009 [101] | 23 MCI | DVR SPM | 23 | 21 | 1 | 0.56 | 2.27 | Small | L |
Population: total number of patients and healthy controls considered in the study. Method: quantitative method applied in the study. Cohort investigated: number of patients considered for sensitivity and specificity estimations. Followup: duration of observational period (for early diagnosis study). Sensitivity and specificity: results of the study. LHR+: likelihood ratio. Increase in the LHR+: increase in the probability of the likelihood of the disease. GRADE: results of GRADE evaluation. Quality of evidence was evaluated based on LHR+ values, LHR+ increase probability, and size of the sample included.
Abbreviations: AD: Alzheimer's disease; FTD: frontotemporal dementia; MCI: mild cognitive impairment; ODD: other dementia; LBD: Lewy body dementia; VaD: vascular dementia; HC: healthy controls.